Charles J Ryan

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/3392194/publications.pdf

Version: 2024-02-01

91	10,883	159358 30	49773 87
papers	citations	h-index	g-index

92	92	92	10219
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Abiraterone and Increased Survival in Metastatic Prostate Cancer. New England Journal of Medicine, 2011, 364, 1995-2005.	13.9	3,736
2	Abiraterone in Metastatic Prostate Cancer without Previous Chemotherapy. New England Journal of Medicine, 2013, 368, 138-148.	13.9	2,412
3	Genomic Hallmarks and Structural Variation in Metastatic Prostate Cancer. Cell, 2018, 174, 758-769.e9.	13.5	459
4	Rucaparib in Men With Metastatic Castration-Resistant Prostate Cancer Harboring a BRCA1 or BRCA2 Gene Alteration. Journal of Clinical Oncology, 2020, 38, 3763-3772.	0.8	448
5	Phase I Clinical Trial of the CYP17 Inhibitor Abiraterone Acetate Demonstrating Clinical Activity in Patients With Castration-Resistant Prostate Cancer Who Received Prior Ketoconazole Therapy. Journal of Clinical Oncology, 2010, 28, 1481-1488.	0.8	369
6	Platinum-Based Chemotherapy for Variant Castrate-Resistant Prostate Cancer. Clinical Cancer Research, 2013, 19, 3621-3630.	3.2	350
7	Analysis of Circulating Cell-Free DNA Identifies Multiclonal Heterogeneity of BRCA2 Reversion Mutations Associated with Resistance to PARP Inhibitors. Cancer Discovery, 2017, 7, 999-1005.	7.7	223
8	Updated Interim Efficacy Analysis and Long-term Safety of Abiraterone Acetate in Metastatic Castration-resistant Prostate Cancer Patients Without Prior Chemotherapy (COU-AA-302). European Urology, 2014, 66, 815-825.	0.9	221
9	Associations of Luminal and Basal Subtyping of Prostate Cancer With Prognosis and Response to Androgen Deprivation Therapy. JAMA Oncology, 2017, 3, 1663.	3.4	219
10	Randomized Controlled Trial of Early Zoledronic Acid in Men With Castration-Sensitive Prostate Cancer and Bone Metastases: Results of CALGB 90202 (Alliance). Journal of Clinical Oncology, 2014, 32, 1143-1150.	0.8	217
11	Phase II Study of Abiraterone Acetate in Chemotherapy-Naive Metastatic Castration-Resistant Prostate Cancer Displaying Bone Flare Discordant with Serologic Response. Clinical Cancer Research, 2011, 17, 4854-4861.	3.2	203
12	Safety and Efficacy of BIND-014, a Docetaxel Nanoparticle Targeting Prostate-Specific Membrane Antigen for Patients With Metastatic Castration-Resistant Prostate Cancer. JAMA Oncology, 2018, 4, 1344.	3.4	169
13	Abiraterone acetate plus prednisone versus prednisone alone in chemotherapy-naive men with metastatic castration-resistant prostate cancer: patient-reported outcome results of a randomised phase 3 trial. Lancet Oncology, The, 2013, 14, 1193-1199.	5.1	142
14	Prediction of overall survival for patients with metastatic castration-resistant prostate cancer: development of a prognostic model through a crowdsourced challenge with open clinical trial data. Lancet Oncology, The, 2017, 18, 132-142.	5.1	124
15	Serum Androgens As Prognostic Biomarkers in Castration-Resistant Prostate Cancer: Results From an Analysis of a Randomized Phase III Trial. Journal of Clinical Oncology, 2013, 31, 2791-2798.	0.8	111
16	Phase 2 Study of the Safety and Antitumor Activity of Apalutamide (ARN-509), a Potent Androgen Receptor Antagonist, in the High-risk Nonmetastatic Castration-resistant Prostate Cancer Cohort. European Urology, 2016, 70, 963-970.	0.9	104
17	Transcriptional profiling identifies an androgen receptor activity-low, stemness program associated with enzalutamide resistance. Proceedings of the National Academy of Sciences of the United States of America, 2020, 117, 12315-12323.	3.3	87
18	Adrenal Androgen Levels as Predictors of Outcome in Prostate Cancer Patients Treated with Ketoconazole Plus Antiandrogen Withdrawal: Results from a Cancer and Leukemia Group B Study. Clinical Cancer Research, 2007, 13, 2030-2037.	3.2	85

#	Article	IF	Citations
19	Intense Exercise for Survival among Men with Metastatic Castrate-Resistant Prostate Cancer (INTERVAL-GAP4): a multicentre, randomised, controlled phase III study protocol. BMJ Open, 2018, 8, e022899.	0.8	85
20	Phase I dose escalation and pharmacokinetic study of AZD2171, an inhibitor of the vascular endothelial growth factor receptor tyrosine kinase, in patients with hormone refractory prostate cancer (HRPC). Investigational New Drugs, 2007, 25, 445-451.	1.2	70
21	A review of prostate cancer treatment impact on the CNS and cognitive function. Prostate Cancer and Prostatic Diseases, 2020, 23, 207-219.	2.0	59
22	NK-Cell-Mediated Targeting of Various Solid Tumors Using a B7-H3 Tri-Specific Killer Engager In Vitro and In Vivo. Cancers, 2020, 12, 2659.	1.7	54
23	Preexisting Levels of CD4 T Cells Expressing PD-1 Are Related to Overall Survival in Prostate Cancer Patients Treated with Ipilimumab. Cancer Immunology Research, 2015, 3, 1008-1016.	1.6	49
24	HSD3B1 and Response to a Nonsteroidal CYP17A1 Inhibitor in Castration-Resistant Prostate Cancer. JAMA Oncology, 2018, 4, 554.	3.4	48
25	Role of secondary hormonal therapy in the management of recurrent prostate cancer. Urology, 2003, 62, 87-94.	0.5	45
26	Germline Genetic Testing in Advanced Prostate Cancer; Practices and Barriers: Survey Results from the Germline Genetics Working Group of the Prostate Cancer Clinical Trials Consortium. Clinical Genitourinary Cancer, 2019, 17, 275-282.e1.	0.9	42
27	Oligometastatic Prostate Cancer: A Shrinking Subset or an Opportunity for Cure?. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2019, 39, 309-320.	1.8	42
28	Radium-223 in combination with docetaxel in patients with castration-resistant prostate cancer and bone metastases: a phase 1 dose escalation/randomised phase 2a trial. European Journal of Cancer, 2019, 114, 107-116.	1.3	42
29	Diet and lifestyle considerations for patients with prostate cancer. Urologic Oncology: Seminars and Original Investigations, 2020, 38, 105-117.	0.8	36
30	Angiogenesis inhibition plus chemotherapy for metastatic hormone refractory prostate cancer: History and rationale. Urologic Oncology: Seminars and Original Investigations, 2006, 24, 250-253.	0.8	35
31	Practical Considerations and Challenges for Germline Genetic Testing in Patients With Prostate Cancer: Recommendations From the Germline Genetics Working Group of the PCCTC. JCO Oncology Practice, 2020, 16, 811-819.	1.4	35
32	Sequential Use of the Androgen Synthesis Inhibitors Ketoconazole and Abiraterone Acetate in Castration-Resistant Prostate Cancer and the Predictive Value of Circulating Androgens. Clinical Cancer Research, 2014, 20, 6269-6276.	3.2	32
33	Abiraterone acetatefor the treatment of prostate cancer. Expert Opinion on Pharmacotherapy, 2013, 14, 91-96.	0.9	29
34	DNA Repair Deficiency Is Common in Advanced Prostate Cancer: New Therapeutic Opportunities. Oncologist, 2016, 21, 940-945.	1.9	29
35	A Phase II Trial of Selinexor, an Oral Selective Inhibitor of Nuclear Export Compound, in Abiraterone- and/or Enzalutamide-Refractory Metastatic Castration-Resistant Prostate Cancer. Oncologist, 2018, 23, 656-e64.	1.9	25
36	Improving research for prostate cancer survivorship: A statement from the Survivorship Research in Prostate Cancer (SuRECaP) working group. Urologic Oncology: Seminars and Original Investigations, 2020, 38, 83-93.	0.8	24

#	Article	IF	Citations
37	Management of Patients with Metastatic Castration-Sensitive Prostate Cancer in the Real-World Setting in the United States. Journal of Urology, 2021, 206, 1420-1429.	0.2	24
38	Co-Inhibition of Androgen Receptor and PARP as a Novel Treatment Paradigm in Prostate Cancerâ€"Where Are We Now?. Cancers, 2022, 14, 801.	1.7	23
39	Exercise in advanced prostate cancer elevates myokine levels and suppresses in-vitro cell growth. Prostate Cancer and Prostatic Diseases, 2022, 25, 86-92.	2.0	23
40	Phase II Study of Ketoconazole Plus Granulocyte-Macrophage Colony-Stimulating Factor for Prostate Cancer: Effect of Extent of Disease on Outcome. Journal of Urology, 2007, 178, 2372-2377.	0.2	21
41	Comparative analysis of antibiotic exposure association with clinical outcomes of chemotherapy versus immunotherapy across three tumour types. ESMO Open, 2020, 5, e000803.	2.0	18
42	High-Dose Abiraterone Acetate in Men With Castration Resistant Prostate Cancer. Clinical Genitourinary Cancer, 2017, 15, 733-741.e1.	0.9	16
43	Prostate cancer update: 2005. Current Opinion in Oncology, 2006, 18, 284-288.	1.1	15
44	Inhibitory effects of nordihydroguaiaretic acid (NDGA) on the IGFâ€1 receptor and androgen dependent growth of LAPCâ€4 prostate cancer cells. Prostate, 2008, 68, 1232-1240.	1.2	15
45	Boneâ€Targeting Radiopharmaceuticals for the Treatment of Boneâ€Metastatic Castrationâ€Resistant Prostate Cancer: Exploring the Implications of New Data. Oncologist, 2014, 19, 1012-1018.	1.9	14
46	Effects of metformin and statins on outcomes in men with castration-resistant metastatic prostate cancer: Secondary analysis of COU-AA-301 and COU-AA-302. European Journal of Cancer, 2022, 170, 296-304.	1.3	14
47	Clinical Variables Associated With Overall Survival in Metastatic Castration-Resistant Prostate Cancer Patients Treated With Sipuleucel-T Immunotherapy. Clinical Genitourinary Cancer, 2018, 16, 184-190.e2.	0.9	13
48	Differential use of medical versus surgical androgen deprivation therapy for patients with metastatic prostate cancer. Cancer, 2019, 125, 453-462.	2.0	13
49	Advances in prostate cancer. Current Opinion in Oncology, 2004, 16, 242-246.	1.1	12
50	BRCAness and prostate cancer: diagnostic and therapeutic considerations. Prostate Cancer and Prostatic Diseases, 2018, 21, 488-498.	2.0	12
51	Identification of patients with metastatic castration-sensitive or metastatic castration-resistant prostate cancer using administrative health claims and laboratory data. Current Medical Research and Opinion, 2021, 37, 609-622.	0.9	12
52	Response to Rucaparib in BRCA-Mutant Metastatic Castration-Resistant Prostate Cancer Identified by Genomic Testing in the TRITON2 Study. Clinical Cancer Research, 2021, 27, 6677-6686.	3.2	12
53	Optimizing the management of castrationâ€resistant prostate cancer patients: A practical guide for clinicians. Prostate, 2020, 80, 1159-1176.	1.2	11
54	Feasibility, safety, and acceptability of a remotely monitored exercise pilot CHAMP: A Clinical trial of Highâ€intensity Aerobic and resistance exercise for Metastatic castrateâ€resistant Prostate cancer. Cancer Medicine, 2021, 10, 8058-8070.	1.3	11

#	Article	IF	Citations
55	A bilingual, Internet-based, targeted advertising campaign for prostate cancer clinical trials: Assessing the feasibility, acceptability, and efficacy of a novel recruitment strategy. Contemporary Clinical Trials Communications, 2018, 12, 60-67.	0.5	10
56	How current reporting practices may mask differences: A call for examining cancer-specific demographic enrollment patterns in cancer treatment clinical trials. Contemporary Clinical Trials Communications, 2019, 16, 100476.	0.5	10
57	Androgen decline and survival during docetaxel therapy in metastatic castration resistant prostate cancer (mCRPC). Prostate Cancer and Prostatic Diseases, 2020, 23, 66-73.	2.0	9
58	Treatment patterns in men with metastatic castration sensitive prostate cancer (mCSPC) in the United States (US).. Journal of Clinical Oncology, 2020, 38, e19131-e19131.	0.8	9
59	A Phase Ib/II Study of the CDK4/6 Inhibitor Ribociclib in Combination with Docetaxel plus Prednisone in Metastatic Castration-Resistant Prostate Cancer. Clinical Cancer Research, 2022, 28, 1531-1539.	3.2	9
60	Novel immune engagers and cellular therapies for metastatic castration-resistant prostate cancer: do we take a BiTe or ride BiKEs, TriKEs, and CARs?. Prostate Cancer and Prostatic Diseases, 2021, 24, 986-996.	2.0	8
61	A multicenter phase I study of cabazitaxel, mitoxantrone, and prednisone for chemotherapy-naÃ¯ve patients with metastatic castration-resistant prostate cancer: A department of defense prostate cancer clinical trials consortium study. Urologic Oncology: Seminars and Original Investigations, 2017, 35, 149.e7-149.e13.	0.8	7
62	Prostate cancer in the era of â€œOmicâ€•medicine: recognizing the importance of DNA damage repair pathways. Annals of Translational Medicine, 2018, 6, 161-161.	0.7	7
63	Examining initial treatment and survival among men with metastatic prostate cancer: An analysis from the CaPSURE registry. Urologic Oncology: Seminars and Original Investigations, 2020, 38, 793.e1-793.e11.	0.8	7
64	Resetting the Bar of Castration Resistance â€“ Understanding Androgen Dynamics in Therapy Resistance and Treatment Choice in Prostate Cancer. Clinical Genitourinary Cancer, 2021, 19, 199-207.	0.9	7
65	Approaches to minimize castration in the treatment of advanced prostate cancer. Urologic Oncology: Seminars and Original Investigations, 2016, 34, 368-374.	0.8	6
66	Assessment and Management of Cognitive Function in Patients with Prostate Cancer Treated with Second-Generation Androgen Receptor Pathway Inhibitors. CNS Drugs, 2022, 36, 419-449.	2.7	6
67	Secondary Hormonal Manipulations in Prostate Cancer. Hematology/Oncology Clinics of North America, 2006, 20, 925-934.	0.9	5
68	Recycling Discarded Drugs: Improving Access to Oral Antineoplastic Drugs. Oncologist, 2019, 24, 291-292.	1.9	5
69	Androgens and Overall Survival in Patients With Metastatic Castration-resistant Prostate Cancer Treated With Docetaxel. Clinical Genitourinary Cancer, 2020, 18, 222-229.e2.	0.9	5
70	Progress in detection and treatment of prostate cancer. Current Opinion in Internal Medicine, 2005, 4, 416-419.	1.5	3
71	Hard Problems Need â€œSoftâ€•Science: Integrating Quality of Life into Treatment Decision Making. European Urology, 2019, 75, 948-949.	0.9	3
72	Use of androgen receptor signaling-targeted therapies in chemotherapy-naive metastatic castration-resistant prostate cancer: a call for patient-centered studies. Journal of Comparative Effectiveness Research, 2016, 5, 5-7.	0.6	2

#	Article	IF	Citations
73	Utility of novel androgen receptor therapies in the real world: A nuanced approach. Urologic Oncology: Seminars and Original Investigations, 2016, 34, 340-347.	0.8	2
74	Impact of clinical versus radiographic progression on clinical outcomes in metastatic castration-resistant prostate cancer. ESMO Open, 2020, 5, e000943.	2.0	2
75	Addressing Cardiovascular Risk of Prostate Cancer Hormonal Therapy. JACC: CardioOncology, 2020, 2, 82-83.	1.7	2
76	Genomic analysis of circulating tumor DNA in 3,334 patients with advanced prostate cancer to identify targetable BRCA alterations and AR resistance mechanisms.. Journal of Clinical Oncology, 2021, 39, 25-25.	0.8	2
77	Combined Longitudinal Clinical and Autopsy Phenomic Assessment in Lethal Metastatic Prostate Cancer: Recommendations for Advancing Precision Medicine. European Urology Open Science, 2021, 30, 47-62.	0.2	2
78	Efficacy and Adverse Events of Docetaxel for Metastatic, Hormone-sensitive Prostate Cancer Among Elderly Men: A Post Hoc Analysis of the CHAARTED Trial. Clinical Genitourinary Cancer, 2021, 19, 388-395.	0.9	2
79	Triple Aberrant Prostate Cancer (TAPC) - Aggregate role of aberrations in , and on ETS gene fusions and prognosis in metastatic castrate resistant prostate cancer. American Journal of Clinical and Experimental Urology, 2020, 8, 106-115.	0.4	2
80	Alliance A031902 (CASPAR): A randomized, phase (ph) 3 trial of enzalutamide with rucaparib/placebo as novel therapy in first-line metastatic castration-resistant prostate cancer (mCRPC).. Journal of Clinical Oncology, 2022, 40, TPS194-TPS194.	0.8	2
81	A phase II trial of abemaciclib (abema) and atezolizumab (atezo) in unselected and CDK12-loss metastatic castration-resistant prostate cancer (mCRPC).. Journal of Clinical Oncology, 2022, 40, TPS213-TPS213.	0.8	2
82	Molecular alterations across sites of metastasis in patients with renal cell carcinoma (RCC).. Journal of Clinical Oncology, 2022, 40, 287-287.	0.8	2
83	Comprehensive genomic profiling of penile squamous cell carcinoma and impact of HPV status on immune-checkpoint inhibition-related biomarkers.. Journal of Clinical Oncology, 2022, 40, 4-4.	0.8	2
84	The Selection of Hormonal Therapy in Prostate Cancer: Who, When, and for How Long?. Journal of the National Comprehensive Cancer Network: JNCCN, 2004, 2, 261-268.	2.3	1
85	Association of ATM mutations in metastatic prostate cancer with differential genomic alteration profiles from homologous recombination deficient and proficient tumors.. Journal of Clinical Oncology, 2021, 39, 5063-5063.	0.8	1
86	Regulatory genes in the androgen production, uptake and conversion (APUC) pathway in advanced prostate cancer. Endocrine Oncology, 2022, 2, R51-R64.	0.1	1
87	Alliance A031902 (CASPAR): A randomized, phase (ph) 3 trial of enzalutamide with rucaparib/placebo in first-line metastatic castration-resistant prostate cancer (mCRPC).. Journal of Clinical Oncology, 2022, 40, TPS5107-TPS5107.	0.8	1
88	Targeting the Androgen Receptor: Remaining questions and future directions. Urologic Oncology: Seminars and Original Investigations, 2016, 34, 339.	0.8	0
89	A phase (Ph) 1b/2 study of ribociclib (R) in combination with docetaxel (D) plus prednisone (P) in metastatic castration-resistant prostate cancer (mCRPC).. Journal of Clinical Oncology, 2021, 39, 5043-5043.	0.8	0
90	Association of polymorphisms in androgen production, uptake, and conversion chain (APUC) genes with mortality of prostate cancer patients.. Journal of Clinical Oncology, 2020, 38, 5528-5528.	0.8	0

#	Article	IF	Citations
91	Molecular and immune landscape of FH-mutated kidney cancer.. Journal of Clinical Oncology, 2022, 40, 382-382.	0.8	0